Volume 25, Number 1—January 2019
Dispatch
Burdens of Invasive Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus Disease, Minnesota, USA
Mackenzie Koeck, Kathryn Como-Sabetti
, Dave Boxrud, Ginette Dobbins, Anita Glennen, Melissa Anacker, Selina Jawahir, Isaac See, and Ruth Lynfield
, Dave Boxrud, Ginette Dobbins, Anita Glennen, Melissa Anacker, Selina Jawahir, Isaac See, and Ruth Lynfield
Table 2
Clonal groups and antimicrobial drug susceptibilities of invasive MSSA and MRSA isolates, Minnesota, USA, August 1, 2014–January 31, 2015*
| Characteristic | MSSA, no. (%), n = 190 | MRSA, no. (%), n = 119 | p value |
|---|---|---|---|
| Clonal group | |||
| USA100 | 13 (7) | 42 (35) | <0.01 |
| USA200 | 26 (14) | 0 (0) | <0.01 |
| USA300 | 5 (3) | 36 (30) | <0.01 |
| USA400 | 1 (1) | 3 (3) | 0.16 |
| USA500 | 2 (1) | 0 (0) | 0.56 |
| USA600 | 13 (7) | 0 (0) | <0.01 |
| USA700 | 5 (3) | 3 (3) | 1.00 |
| USA900 | 10 (5) | 0 (0) | <0.01 |
| USA1000 | 6 (3) | 0 (0) | 0.09 |
| USA1200 | 2 (1) | 0 (0) | 0.56 |
| Untypeable | 2 (1) | 0 (0) | 0.56 |
| No USA group | 105 (55) | 35 (29) | <0.01 |
| Antimicrobial drug† | |||
| Clindamycin‡ | 176 (93) | 61 (51) | <0.01 |
| Ceftaroline | 190 (100) | 117 (98) | 0.15 |
| Doxycycline | 185 (97) | 118 (99) | 0.41 |
| Erythromycin | 143 (75) | 18 (15) | <0.01 |
| Gentamicin | 189 (99) | 118 (99) | 1.00 |
| Levofloxacin | 175 (92) | 35 (29) | <0.01 |
| Penicillin | 63 (33) | 0 (0) | <0.01 |
| Rifampin | 189 (99) | 118 (99) | 1.00 |
| Tetracycline | 177 (93) | 118 (99) | 0.01 |
| Trimethoprim/sulfamethoxazole | 188 (99) | 119 (100) | 0.53 |
*MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible S. aureus.
†Proportions represent isolates susceptible to an antimicrobial drug. All isolates were susceptible to daptomycin, linezolid, telavancin, and vancomycin. A total of invasive MSSA and MRSA isolates had vancomycin MICs <0.05; 86% of invasive MSSA isolates and 81% of invasive MSSA isolates had vancomycin MICs = 1; 13% of invasive MSSA isolates and 18% of invasive MRSA isolates had vancomycin MICs = 2.
‡Isolates with inducible clindamycin resistance were classified as nonsusceptible.
Page created: December 18, 2018
Page updated: December 18, 2018
Page reviewed: December 18, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.